We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OptimizeRx (OPRX) to Report Q2 Earnings: What's in Store?
Read MoreHide Full Article
OptimizeRx Corp. (OPRX - Free Report) is scheduled to report second-quarter 2019 results on Aug 7.
In the last reported quarter, the company came up with a positive surprise of 100%. In fact, the company’s earnings history is impressive, having trumped the Zacks Consensus Estimate in each of the trailing four quarters, the average being 133.33%.
Meanwhile, revenues of $5 million in the same period matched the Zacks Consensus Estimate. The same, however, improved 27% from the year-ago quarter.
The Zacks Consensus Estimate for second-quarter 2019 revenues is pegged at $6.8 million, indicating a nearly 32.9% increase from the year-ago reported figure.
The Zacks Consensus Estimate for earnings stands at 8 cents, suggesting a 300% surge from the number reported in the prior-year quarter.
Let’s see how things are shaping up for the upcoming announcement.
Factors to Consider
OptimizeRx’s performance in the upcoming quarterly results is likely to be driven by its diversified revenue streams, broader provider reach, scalable technology and strong operational efficiency.
The company’s focus on expanding its channel partners is also likely to expand transaction volume this earnings season. Increased sales of core financial and brand messaging products are expected to boost the quarterly results.
Moreover, the CareSpeak buyout is a positive. Additionally, expanded platform integrations with leading electronic health record systems, such as Epic and Cerner in the last reported quarter make us optimistic.
Further, a favorable product mix shift is expected to boost gross margins in the soon-to-be-reported quarter. However, expenses related to the integration of CareSpeak are an overhang.
The proven Zacks model shows that a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has maximum chances of beating estimates if it also has a positive Earnings ESP. Zacks Rank #4 (Sell) or 5 (Strong Sell) stocks are best avoided. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
OptimizeRx currently carries a Zacks Rank #2, which increases the predictive power of ESP. However, its Earnings ESP of 0.00% in the combination makes surprise prediction difficult for the stock.
Stocks to Consider
Here are a couple of stocks worth considering as our model shows that these have the right combination of elements to beat on earnings in their upcoming releases:
GTT Communications, Inc. has an Earnings ESP of +144.44% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
OptimizeRx (OPRX) to Report Q2 Earnings: What's in Store?
OptimizeRx Corp. (OPRX - Free Report) is scheduled to report second-quarter 2019 results on Aug 7.
In the last reported quarter, the company came up with a positive surprise of 100%. In fact, the company’s earnings history is impressive, having trumped the Zacks Consensus Estimate in each of the trailing four quarters, the average being 133.33%.
Meanwhile, revenues of $5 million in the same period matched the Zacks Consensus Estimate. The same, however, improved 27% from the year-ago quarter.
The Zacks Consensus Estimate for second-quarter 2019 revenues is pegged at $6.8 million, indicating a nearly 32.9% increase from the year-ago reported figure.
The Zacks Consensus Estimate for earnings stands at 8 cents, suggesting a 300% surge from the number reported in the prior-year quarter.
Let’s see how things are shaping up for the upcoming announcement.
Factors to Consider
OptimizeRx’s performance in the upcoming quarterly results is likely to be driven by its diversified revenue streams, broader provider reach, scalable technology and strong operational efficiency.
The company’s focus on expanding its channel partners is also likely to expand transaction volume this earnings season. Increased sales of core financial and brand messaging products are expected to boost the quarterly results.
Moreover, the CareSpeak buyout is a positive. Additionally, expanded platform integrations with leading electronic health record systems, such as Epic and Cerner in the last reported quarter make us optimistic.
Further, a favorable product mix shift is expected to boost gross margins in the soon-to-be-reported quarter. However, expenses related to the integration of CareSpeak are an overhang.
OptimizeRx Corp. Price and EPS Surprise
OptimizeRx Corp. price-eps-surprise | OptimizeRx Corp. Quote
What Our Model Says
The proven Zacks model shows that a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has maximum chances of beating estimates if it also has a positive Earnings ESP. Zacks Rank #4 (Sell) or 5 (Strong Sell) stocks are best avoided. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
OptimizeRx currently carries a Zacks Rank #2, which increases the predictive power of ESP. However, its Earnings ESP of 0.00% in the combination makes surprise prediction difficult for the stock.
Stocks to Consider
Here are a couple of stocks worth considering as our model shows that these have the right combination of elements to beat on earnings in their upcoming releases:
Ciena Corporation (CIEN - Free Report) has an Earnings ESP of +5.26% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
GTT Communications, Inc. has an Earnings ESP of +144.44% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>